Advances on the Roles of Tenascin-C in Cancer

Overview

Journal J Cell Sci

Specialty Cell Biology

Date 2022 Sep 14

PMID 36102918

Authors

Alev Yilmaz

Thomas Loustau

Nathalie Salome

Suchithra Poilil Surendran

Chengbei Li

Richard P Tucker

Valerio Izzi

Rijuta Lamba

Manuel Koch

Gertraud Orend

Affiliations

Soon will be listed here.

Abstract

The roles of the extracellular matrix molecule tenascin-C (TNC) in health and disease have been extensively reviewed since its discovery over 40 years ago. Here, we will describe recent insights into the roles of TNC in tumorigenesis, angiogenesis, immunity and metastasis. In addition to high levels of expression in tumors, and during chronic inflammation, and bacterial and viral infection, TNC is also expressed in lymphoid organs. This supports potential roles for TNC in immunity control. Advances using murine models with engineered TNC levels were instrumental in the discovery of important functions of TNC as a danger-associated molecular pattern (DAMP) molecule in tissue repair and revealed multiple TNC actions in tumor progression. TNC acts through distinct mechanisms on many different cell types with immune cells coming into focus as important targets of TNC in cancer. We will describe how this knowledge could be exploited for cancer disease management, in particular for immune (checkpoint) therapies.

Citing Articles

The role of tenascin-C in tumor microenvironments and its potential as a therapeutic target.

Wang Y, Wen X, Su C, You Y, Jiang Z, Fan Q Front Cell Dev Biol. 2025; 13:1554312.

PMID: 40046232 PMC: 11879967. DOI: 10.3389/fcell.2025.1554312.

Revealing the role of RAB27 in HER receptor family expression and signaling in melanoma cells.

Horodecka K, Czernek L, Peczek L, Klink M Cell Commun Signal. 2025; 23(1):118.

PMID: 40038749 PMC: 11877929. DOI: 10.1186/s12964-025-02064-8.

Negative regulation of lymphangiogenesis by Tenascin-C delays the resolution of inflammation.

Katoh D, Senga Y, Mizutani K, Maruyama K, Yamakawa D, Yamamuro T iScience. 2025; 28(2):111756.

PMID: 39925433 PMC: 11803235. DOI: 10.1016/j.isci.2025.111756.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.

Cao Z, Quazi S, Arora S, Osellame L, Burvenich I, Janes P J Biomed Sci. 2025; 32(1):7.

PMID: 39780187 PMC: 11715488. DOI: 10.1186/s12929-024-01099-2.

References

Midwood K, Orend G . The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009; 3(3-4):287-310. PMC: 2778592. DOI: 10.1007/s12079-009-0075-1. View

Fares C, Van Allen E, Drake C, Allison J, Hu-Lieskovan S . Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. Am Soc Clin Oncol Educ Book. 2019; 39:147-164. DOI: 10.1200/EDBK_240837. View

OConnell J, Sugimoto H, Cooke V, MacDonald B, Mehta A, LeBleu V . VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A. 2011; 108(38):16002-7. PMC: 3179047. DOI: 10.1073/pnas.1109493108. View

Mirzaei R, Sarkar S, Dzikowski L, Rawji K, Khan L, Faissner A . Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oncoimmunology. 2018; 7(10):e1478647. PMC: 6169571. DOI: 10.1080/2162402X.2018.1478647. View

Tanaka R, Seki Y, Saito Y, Kamiya S, Fujita M, Okutsu H . Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and platelet-derived growth factor (PDGF)-dependent cell proliferation through potentiated and sustained activation of integrin α5β1. J Biol Chem. 2014; 289(25):17699-708. PMC: 4067204. DOI: 10.1074/jbc.M113.546622. View

Liu R, He Y, Li B, Liu J, Ren Y, Han W . Tenascin-C produced by oxidized LDL-stimulated macrophages increases foam cell formation through Toll-like receptor-4. Mol Cells. 2012; 34(1):35-41. PMC: 3887780. DOI: 10.1007/s10059-012-0054-x. View

Lange K, Kammerer M, Hegi M, Grotegut S, Dittmann A, Huang W . Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res. 2007; 67(13):6163-73. DOI: 10.1158/0008-5472.CAN-06-3348. View

Cueni L, Hegyi I, Shin J, Albinger-Hegyi A, Gruber S, Kunstfeld R . Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol. 2010; 177(2):1004-16. PMC: 2913355. DOI: 10.2353/ajpath.2010.090703. View

Shields J, Kourtis I, Tomei A, Roberts J, Swartz M . Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 2010; 328(5979):749-52. DOI: 10.1126/science.1185837. View

10.

Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y . Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol. 2011; 178(2):754-63. PMC: 3069868. DOI: 10.1016/j.ajpath.2010.10.015. View

11.

Zemek R, Chin W, Nowak A, Millward M, Lake R, Lesterhuis W . Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Front Immunol. 2020; 11:223. PMC: 7040078. DOI: 10.3389/fimmu.2020.00223. View

12.

Onion D, Isherwood M, Shridhar N, Xenophontos M, Craze M, Day L . Multicomponent analysis of the tumour microenvironment reveals low CD8 T cell number, low stromal caveolin-1 and high tenascin-C and their combination as significant prognostic markers in non-small cell lung cancer. Oncotarget. 2018; 9(2):1760-1771. PMC: 5788597. DOI: 10.18632/oncotarget.18880. View

13.

Midwood K, Mao Y, Hsia H, Valenick L, Schwarzbauer J . Modulation of cell-fibronectin matrix interactions during tissue repair. J Investig Dermatol Symp Proc. 2006; 11(1):73-8. DOI: 10.1038/sj.jidsymp.5650005. View

14.

Hongu T, Pein M, Insua-Rodriguez J, Gutjahr E, Mattavelli G, Meier J . Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs. Nat Cancer. 2022; 3(4):486-504. PMC: 9046090. DOI: 10.1038/s43018-022-00353-6. View

15.

Chen S, Fu H, Wu S, Zhu W, Liao J, Hong X . Tenascin-C protects against acute kidney injury by recruiting Wnt ligands. Kidney Int. 2018; 95(1):62-74. PMC: 6320278. DOI: 10.1016/j.kint.2018.08.029. View

16.

Luond F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F . Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021; 56(23):3203-3221.e11. DOI: 10.1016/j.devcel.2021.11.006. View

17.

Rai A, Greening D, Chen M, Xu R, Ji H, Simpson R . Exosomes Derived from Human Primary and Metastatic Colorectal Cancer Cells Contribute to Functional Heterogeneity of Activated Fibroblasts by Reprogramming Their Proteome. Proteomics. 2018; 19(8):e1800148. DOI: 10.1002/pmic.201800148. View

18.

Zhu H, Liao J, Zhou X, Hong X, Song D, Hou F . Tenascin-C promotes acute kidney injury to chronic kidney disease progression by impairing tubular integrity via αvβ6 integrin signaling. Kidney Int. 2020; 97(5):1017-1031. PMC: 8112450. DOI: 10.1016/j.kint.2020.01.026. View

19.

Saito Y, Imazeki H, Miura S, Yoshimura T, Okutsu H, Harada Y . A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem. 2007; 282(48):34929-37. DOI: 10.1074/jbc.M705608200. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View